Gilead Looks to Machine Learning with insitro NASH Collaboration

By Michelle Liu

Pharma Deals Review: Vol 2019 Issue 4 (Table of Contents)

Published: 25 Apr-2019

DOI: 10.3833/pdr.v2019.i4.2419     ISSN: 1756-7874

Section: Research & Development



Undeterred by the failure of its lead non-alcoholic steatohepatitis (NASH) drug, selonsertib, in a key Phase III trial as announced in February 2019, Gilead has agreed to a three-year collaboration with insitro to develop NASH therapies for up to five targets...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details